Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Allergan, ForSight Vision5 deal

    Allergan plc (NYSE:AGN), Dublin, Ireland ForSight Vision5 Inc., Menlo Park, Calif. Business: Ophthalmic Allergan acquired ForSight Vision5 for $95 million in cash and an undisclosed milestone tied to the launch of …

    Published on 8/22/2016
  • BioNano Genomics, Berry Genomics deal

    BioNano Genomics Inc., San Diego, Calif. Berry Genomics Co. Ltd., Beijing, China Business: Genomics BioNano and Berry partnered to co-develop a next-generation genomic mapping system in China. The companies will use …

    Published on 8/22/2016
  • Boehringer Ingelheim, Canbridge deal

    Boehringer Ingelheim GmbH, Ingelheim, Germany Canbridge Life Sciences Ltd., Beijing, China Business: Cancer Boehringer will manufacture Canbridges AV-203 (CAN-017) in Shanghai. AV-203, an Erb-b2 receptor tyrosine kinase…

    Published on 8/22/2016
  • Catalyst Biosciences, Attenua deal

    Catalyst Biosciences Inc. (NASDAQ:CBIO), South San Francisco, Calif. Attenua Inc., New York, N.Y. Business: Pulmonary Catalyst will sell TC-5619, TC-6987 and TC-6683 (AZD1446) to Attenua for $1 million up front and for …

    Published on 8/22/2016
  • Celsion, Zhejiang Hisun Pharmaceutical deal

    Celsion Corp. (NASDAQ:CLSN;Tel Aviv:CLSN), Lawrenceville, N.J. Zhejiang Hisun Pharmaceutical Co. Ltd. (Shanghai:600267), Taizhou City, China Business: Cancer, Gene/Cell therapy Celsion and Hisun partnered to manufacture…

    Published on 8/22/2016
  • Dyadic International, Sanofi, EnGen Bio deal

    Dyadic International Inc. (OTCQX:DYAI), Jupiter, Fla. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France EnGen Bio Inc., San Mateo, Calif. Business: Biomanufacturing Dyadic said Sanofis Sanofi Pasteur S.A. vaccines unit will…

    Published on 8/22/2016
  • Evelo, Mayo Clinic deal

    Evelo Biosciences Inc., Cambridge, Mass. Mayo Clinic, Rochester, Minn. Business: Cancer Evelo and Mayo Clinical partnered exclusively to isolate and characterize cancer-associated bacteria from patient stool samples and…

    Published on 8/22/2016
  • Gedeon Richter, Recordati deal

    Gedeon Richter Ltd. (Budapest:RICHTER), Budapest, Hungary Recordati S.p.A. (Milan:REC), Milan, Italy Business: Neurology Gedeon Richter granted Recordati exclusive rights to commercialize schizophrenia drug cariprazine …

    Published on 8/22/2016
  • Imanis Life Sciences, Vyriad deal

    Imanis Life Sciences LLC, Rochester, Minn. Vyriad, Rochester, Minn. Business: Pharmacogenetics Vyriad and Imanis partnered to develop companion diagnostics to assess the probability of a cancer patient responding to …

    Published on 8/22/2016
  • Indivumed, Pacific Northwest Diabetes Research Institute deal

    Indivumed GmbH, Hamburg, Germany Pacific Northwest Diabetes Research Institute, Seattle, Wash. Business: Cancer Indivumed and the institute partnered to use PNRIs computation method to analyze Indivumeds Cancer Database…

    Published on 8/22/2016
  • Innovative Targeting Solutions, Zymeworks deal

    Innovative Targeting Solutions Inc., Burnaby, B.C. Zymeworks Inc., Vancouver, B.C. Business: Antibodies Innovative Targeting granted Zymeworks rights to the human antibody and human T cell receptor generating platform …

    Published on 8/22/2016
  • IntelGenx, SWK Holdings deal

    IntelGenx Corp. (TSX-V:IGX;OTCQX:IGXT), Saint-Laurent, Quebec SWK Holdings Corp. (OTCBB:SWKH), Dallas, Texas Business: Neurology, Drug delivery IntelGenx sold its royalty rights for Forfivo XL bupropion to SWK Holdings …

    Published on 8/22/2016
  • Lees Pharmaceutical Holdings Ltd., ScinoPharm Taiwan deal

    Lees Pharmaceutical Holdings Ltd. (HKSE:0950), Hong Kong, China ScinoPharm Taiwan Ltd. (Taiwan:1789), Tainan, Taiwan Business: Cardiovascular Lees Pharmaceuticals CVie Therapeutics Ltd. subsidiary and ScinoPharm …

    Published on 8/22/2016
  • Medivir, Trek Therapeutics deal

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Trek Therapeutics PBC, Cambridge, Mass. Business: Infectious Medivir granted Trek exclusive, worldwide rights outside of Taiwan and China, including Hong Kong and Macau, to …

    Published on 8/22/2016
  • Menlo Therapeutics, Japan Tobacco, Torii deal

    Menlo Therapeutics Inc., Menlo Park, Calif. Japan Tobacco Inc. (Tokyo:2914), Tokyo, Japan Torii Pharmaceutical Co. Ltd. (Tokyo:4551), Tokyo, Japan Business: Dermatology Menlo Therapeutics granted Japan Tobacco and its …

    Published on 8/22/2016
  • Norgine, Valeant Pharmaceuticals deal

    Norgine B.V., Amsterdam, the Netherlands Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Laval, Quebec Business: Gastrointestinal Norgine granted Valeant rights to develop and commercialize NER1006, an …

    Published on 8/22/2016
  • Philogen, J&J deal

    Philogen S.p.A., Siena, Italy Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Pharmaceuticals Philogen and Johnson & Johnsons Janssen Biotech Inc. subsidiary partnered to discover and develop …

    Published on 8/22/2016
  • Protagen, Werfen deal

    Protagen AG, Dortmund, Germany Werfen Group S.A., Barcelona, Spain Business: Diagnostic Protagen granted Werfens Inova Diagnostics Inc. company semi-exclusive rights to develop and commercialize biomarker bicaudal D …

    Published on 8/22/2016
  • Rasna, Active With Me deal

    Rasna Therapeutics Inc. (Pink:ATVM), New York, N.Y. Active With Me Inc., Sarnia, Ontario Business: Cancer Rasna reverse-merged with Active With Me. The combined company retained Rasnas name and will focus on modulating …

    Published on 8/22/2016
  • Sorrento deal

    Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Business: Neurology Sorrento will spin out its Scintilla Pharmaceuticals Inc. subsidiary as an independent company focused on pain management. The separation …

    Published on 8/22/2016
  • Valeant Pharmaceuticals, Pharming deal

    Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Laval, Quebec Pharming Group N.V. (Euronext:PHARM), Leiden, the Netherlands Business: Inflammation Pharming will pay Valeant $60 million up front and up to…

    Published on 8/22/2016
  • Acetylon, Celgene deal

    Acetylon Pharmaceuticals Inc., Boston, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Celgene revealed in a regulatory filing that it did not exercise its option to acquire Acetylon. Celgene allowed …

    Published on 8/15/2016
  • Adverum, Editas Medicine deal

    Adverum Biotechnologies Inc. (NASDAQ:ADVM), Menlo Park, Calif. Editas Medicine Inc. (NASDAQ:EDIT), Cambridge, Mass. Business: Gene/Cell therapy, Ophthalmic Editas and Adverum partnered to develop gene editing-based …

    Published on 8/15/2016
  • Amoy Diagnostics, Merck KGaA deal

    Amoy Diagnostics Co. Ltd., Xiamen, China Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Diagnostic Merck and Amoy partnered to develop and commercialize a liquid biopsy biomarker test that will assess Ras mutation…

    Published on 8/15/2016
  • Bill & Melinda Gates Foundation, Biogen deal

    Bill & Melinda Gates Foundation, Seattle, Wash. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Biomanufacturing Biogen will co-fund a project with the foundation to improve production and manufacturing techniques…

    Published on 8/15/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993